Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
8(62%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
12
92%
Ph phase_3
1
8%

Phase Distribution

0

Early Stage

12

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
12(92.3%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

8

trials recruiting

Total Trials

13

all time

Status Distribution
Active(9)
Completed(1)
Terminated(1)
Other(2)

Detailed Status

Recruiting6
unknown2
Active, not recruiting2
Terminated1
Not yet recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
8
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 212 (92.3%)
Phase 31 (7.7%)

Trials by Status

unknown215%
terminated18%
not_yet_recruiting18%
completed18%
recruiting646%
active_not_recruiting215%

Recent Activity

8 active trials
Showing 5 of 13
recruitingphase_3

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

NCT06255392
recruitingphase_2

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

NCT06288360
recruitingphase_2

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

NCT06718205
recruitingphase_2

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

NCT06289751
recruitingphase_2

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

NCT06100497
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06255392Phase 3

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Recruiting
NCT06288360Phase 2

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Recruiting
NCT06718205Phase 2

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Recruiting
NCT06289751Phase 2

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Recruiting
NCT06100497Phase 2

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Recruiting
NCT06412471Phase 2

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

Recruiting
NCT05807542Phase 2

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

Completed
NCT04844385Phase 2

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Active Not Recruiting
NCT04172259Phase 2

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Active Not Recruiting
NCT05596890Phase 2

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

Unknown
NCT05322499Phase 2

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Unknown
NCT05095467Phase 2

HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction

Not Yet Recruiting
NCT03585062Phase 2

Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer

Terminated

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13